Please fill out the pre-assessment below before the session begins.

1. What agent in combination with romidepsin has recently been added as a recommended regimen in second-line and beyond for patients with PTCL?
2. What is the mechanism of action of Soquelitinib (CPI-818), which was granted fast track designation for the treatment of adult patients with R/R PTCL?
3. Denileukin diftitox, an IL2-receptor-directed cytotoxin, has been approved for the treatment of adults with R/R stage I-III CTCL. What risk must be evaluated for patients with CTCL treated with Denileukin diftitox?
Scroll to Top